An expanded polytetrafluoroethylene substrate comprising a microporous microstructure, an interlayer over at least a portion of the microstructure, the interlayer containing a reactive functionality, and a functional layer attached to the interlayer, the interlayer comprising a sol-gel coating or a polyvinylalcohol. The functional layer of the substrate having functional sites with a density of at least 50 nanomoles/cm.sup.2.

An expanded polytetrafluoroethylene substrate comprising a microporous microstructure, an interlayer over at least a portion of the microstructure, the interlayer containing a reactive functionality, and a functional layer attached to the interlayer, the interlayer comprising a sol-gel coating or a polyvinylalcohol. The functional layer of the substrate having functional sites with a density of at least 50 nanomoles/cm.sup.2.

Compositions comprising multiple hydrogel particles having substantially the same diameter, but with each subgrouping of particles from the multiple hydrogel particles having different associated values for one or more passive optical properties that can be deconvoluted using cytometric instrumentation. Each hydrogel particle from the multiple hydrogel particles can be functionalized with a different biochemical or chemical target from a set of targets. A method of preparing hydrogel particles includes forming droplets and polymerizing the droplets, with optional functionalization.

The present disclosure provides a kit for detecting an anti-vinculin-immunoglobulin G (IgG) antibody, including the antigen protein vinculin, a solid phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate color development reagent, a washing solution, a standard, a positive quality control, and negative quality control. In the present disclosure, the kit can detect the anti-Vinculin-IgG antibody in a sample to be tested by indirect reaction combined with magnetic particle-based chemiluminescence immunoassay. Autoantibodies against the target antigen vinculin are identified in the serum of a patient with autoimmune nephrotic syndrome for the first time, and a detection kit is provided for the autoantibodies. The present disclosure provides a basis for molecular mechanism research and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to vinculin and vinculin-IgG autoantibodies at home and abroad.

The present disclosure provides a kit for detecting an anti-vinculin-immunoglobulin G (IgG) antibody, including the antigen protein vinculin, a solid phase carrier, a labeled antibody, an antigen diluent, a sample dilution buffer, an antibody diluent, a substrate color development reagent, a washing solution, a standard, a positive quality control, and negative quality control. In the present disclosure, the kit can detect the anti-Vinculin-IgG antibody in a sample to be tested by indirect reaction combined with magnetic particle-based chemiluminescence immunoassay. Autoantibodies against the target antigen vinculin are identified in the serum of a patient with autoimmune nephrotic syndrome for the first time, and a detection kit is provided for the autoantibodies. The present disclosure provides a basis for molecular mechanism research and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to vinculin and vinculin-IgG autoantibodies at home and abroad.

It is provided a reversible streptavidin based analyte enrichment system for use in crosslinking mass spectrometry analysis, in particular for enriching at least parts of crosslinked peptides pairs in mass spectrometry analysis, and a method of enriching at least parts of crosslinked peptides pairs, in particular for use in crosslinking mass spectroscopy analysis.

It is provided a reversible streptavidin based analyte enrichment system for use in crosslinking mass spectrometry analysis, in particular for enriching at least parts of crosslinked peptides pairs in mass spectrometry analysis, and a method of enriching at least parts of crosslinked peptides pairs, in particular for use in crosslinking mass spectroscopy analysis.

The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.

The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.

The present invention relates to a conjugate for photodynamic diagnosis or treatment in which a peptide binds with a photosensitizer via an intracellularly degradable linkage, and to a composition for photodynamic diagnosis or treatment including the same.